- Home
- JXG vs PRTG Comparison
JXG vs PRTG Comparison
Compare JXG & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- PRTG
- Stock Information
- Founded
- JXG N/A
- PRTG 1973
- Country
- JXG China
- PRTG British Virgin Islands
- Employees
- JXG N/A
- PRTG N/A
- Industry
- JXG
- PRTG Oil & Gas Production
- Sector
- JXG
- PRTG Energy
- Exchange
- JXG Nasdaq
- PRTG Nasdaq
- Market Cap
- JXG 5.2M
- PRTG 4.7M
- IPO Year
- JXG N/A
- PRTG N/A
- Fundamental
- Price
- JXG $2.58
- PRTG $4.00
- Analyst Decision
- JXG
- PRTG
- Analyst Count
- JXG 0
- PRTG 0
- Target Price
- JXG N/A
- PRTG N/A
- AVG Volume (30 Days)
- JXG 73.9K
- PRTG 65.1K
- Earning Date
- JXG 12-06-2024
- PRTG 02-26-2025
- Dividend Yield
- JXG N/A
- PRTG N/A
- EPS Growth
- JXG N/A
- PRTG N/A
- EPS
- JXG 2.20
- PRTG N/A
- Revenue
- JXG $38,490,872.00
- PRTG N/A
- Revenue This Year
- JXG N/A
- PRTG N/A
- Revenue Next Year
- JXG N/A
- PRTG N/A
- P/E Ratio
- JXG $1.14
- PRTG N/A
- Revenue Growth
- JXG N/A
- PRTG N/A
- 52 Week Low
- JXG $0.75
- PRTG $2.10
- 52 Week High
- JXG $8.51
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- PRTG 41.86
- Support Level
- JXG N/A
- PRTG $3.86
- Resistance Level
- JXG N/A
- PRTG $4.40
- Average True Range (ATR)
- JXG 0.00
- PRTG 0.45
- MACD
- JXG 0.00
- PRTG -0.09
- Stochastic Oscillator
- JXG 0.00
- PRTG 11.11
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc, formerly JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.